ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt

Standard

ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis. / Christoffersen, Christina; Bartels, Emil D.; Pedersen, Annemarie Aarup; Nielsen, Lars Bo; Pedersen, Tanja X.

I: European Journal of Pharmacology, Bind 816, 12.2017, s. 154-160.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt

Harvard

Christoffersen, C, Bartels, ED, Pedersen, AA, Nielsen, LB & Pedersen, TX 2017, 'ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis', European Journal of Pharmacology, bind 816, s. 154-160. https://doi.org/10.1016/j.ejphar.2017.03.053

APA

Christoffersen, C., Bartels, E. D., Pedersen, A. A., Nielsen, L. B., & Pedersen, T. X. (2017). ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis. European Journal of Pharmacology, 816, 154-160. https://doi.org/10.1016/j.ejphar.2017.03.053

Vancouver

Christoffersen C, Bartels ED, Pedersen AA, Nielsen LB, Pedersen TX. ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis. European Journal of Pharmacology. 2017 dec.;816:154-160. https://doi.org/10.1016/j.ejphar.2017.03.053

Author

Christoffersen, Christina ; Bartels, Emil D. ; Pedersen, Annemarie Aarup ; Nielsen, Lars Bo ; Pedersen, Tanja X. / ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis. I: European Journal of Pharmacology. 2017 ; Bind 816. s. 154-160.

Bibtex

@article{90b38ed3581c4ca78fdc1449f79bc955,
title = "ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis",
abstract = "Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.",
keywords = "ApoB, ApoM, Atherosclerosis, Lipoprotein(a), S1P, Uremia",
author = "Christina Christoffersen and Bartels, {Emil D.} and Pedersen, {Annemarie Aarup} and Nielsen, {Lars Bo} and Pedersen, {Tanja X.}",
year = "2017",
month = dec,
doi = "10.1016/j.ejphar.2017.03.053",
language = "English",
volume = "816",
pages = "154--160",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

AU - Christoffersen, Christina

AU - Bartels, Emil D.

AU - Pedersen, Annemarie Aarup

AU - Nielsen, Lars Bo

AU - Pedersen, Tanja X.

PY - 2017/12

Y1 - 2017/12

N2 - Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.

AB - Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.

KW - ApoB

KW - ApoM

KW - Atherosclerosis

KW - Lipoprotein(a)

KW - S1P

KW - Uremia

U2 - 10.1016/j.ejphar.2017.03.053

DO - 10.1016/j.ejphar.2017.03.053

M3 - Journal article

C2 - 28351665

AN - SCOPUS:85016566112

VL - 816

SP - 154

EP - 160

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -

ID: 178848251